{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T22:47:52Z","timestamp":1763592472996,"version":"3.45.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,19]]},"DOI":"10.7759\/cureus.97268","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T22:45:07Z","timestamp":1763592307000},"source":"Crossref","is-referenced-by-count":0,"title":["Sarcomatoid and Unclassified Renal Neoplasms: Histology, Immunology, and Genomics"],"prefix":"10.7759","author":[{"given":"Hussein","family":"Qasim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Hayajneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Abuuqteish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karis","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Luigi Giuseppe","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh JJ","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, et al.. Renal cell carcinoma. Nat Rev Dis Primers. 2017, 3:17009. 10.1038\/nrdp.2017.9","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251345722","article-title":"Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies","volume":"17","author":"Yildirim A","year":"2025","unstructured":"Yildirim A, Moses MW, Gerke M, Jani Y, Thompson JC, Akova U, Bilen MA. Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies. Ther Adv Med Oncol. 2025, 17:17588359251345722. 10.1177\/17588359251345722","journal-title":"Ther Adv Med Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S154932","article-title":"Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities","volume":"10","author":"Sirohi D","year":"2018","unstructured":"Sirohi D, Smith SC, Agarwal N, Maughan BL. Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. Res Rep Urol. 2018, 10:205-17. 10.2147\/RRU.S154932","journal-title":"Res Rep Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: biology, natural history and management","volume":"17","author":"Blum KA","year":"2020","unstructured":"Blum KA, Gupta S, Tickoo SK, et al.. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020, 17:659-78. 10.1038\/s41585-020-00382-9","journal-title":"Nat Rev Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0227","article-title":"Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies","volume":"17","author":"Shuch B","year":"2012","unstructured":"Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist. 2012, 17:46-54. 10.1634\/theoncologist.2011-0227","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010099","article-title":"Sarcomatoid dedifferentiation in renal cell carcinoma: from novel molecular insights to new clinical opportunities","volume":"12","author":"Debien V","year":"2019","unstructured":"Debien V, Thouvenin J, Lindner V, Barth\u00e9l\u00e9my P, Lang H, Flippot R, Malouf GG. Sarcomatoid dedifferentiation in renal cell carcinoma: from novel molecular insights to new clinical opportunities. Cancers (Basel). 2019, 12:99. 10.3390\/cancers12010099","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.2017.70","article-title":"The pathology and molecular genetics of sarcomatoid renal cell carcinoma: a mini-review","volume":"4","author":"Wei S","year":"2017","unstructured":"Wei S, Al-Saleem T. The pathology and molecular genetics of sarcomatoid renal cell carcinoma: a mini-review. J Kidney Cancer VHL. 2017, 4:19-23. 10.15586\/jkcvhl.2017.70","journal-title":"J Kidney Cancer VHL"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s42047-020-00084-x","article-title":"Classification of renal cell tumors - current concepts and use of ancillary tests: recommendations of the Brazilian Society of Pathology","volume":"4","author":"Athanazio DA","year":"2021","unstructured":"Athanazio DA, Amorim LS, da Cunha IW, et al.. Classification of renal cell tumors - current concepts and use of ancillary tests: recommendations of the Brazilian Society of Pathology. Surg Exp Pathol. 2021, 4:4. 10.1186\/s42047-020-00084-x","journal-title":"Surg Exp Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102191","article-title":"Non-clear cell renal carcinomas: review of new molecular insights and recent clinical data","volume":"97","author":"Barth\u00e9l\u00e9my P","year":"2021","unstructured":"Barth\u00e9l\u00e9my P, Rioux-Leclercq N, Thibault C, et al.. Non-clear cell renal carcinomas: review of new molecular insights and recent clinical data. Cancer Treat Rev. 2021, 97:102191. 10.1016\/j.ctrv.2021.102191","journal-title":"Cancer Treat Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101418","article-title":"The morphological spectrum of papillary renal cell carcinoma and prevalence of provisional\/emerging renal tumor entities with papillary growth","volume":"9","author":"Lobo J","year":"2021","unstructured":"Lobo J, Ohashi R, Helmchen BM, Rupp NJ, R\u00fcschoff JH, Moch H. The morphological spectrum of papillary renal cell carcinoma and prevalence of provisional\/emerging renal tumor entities with papillary growth. Biomedicines. 2021, 9:1418. 10.3390\/biomedicines9101418","journal-title":"Biomedicines"},{"key":"ref11","article-title":"Clear cell papillary renal cell carcinoma: a review","volume":"7","author":"Kuroda N","year":"2014","unstructured":"Kuroda N, Ohe C, Kawakami F, et al.. Clear cell papillary renal cell carcinoma: a review. Int J Clin Exp Pathol. 2014, 7:7312-8.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2013.495","article-title":"Sarcomatoid renal cell carcinoma with rhabdoid features","volume":"33","author":"Al-Saidi NA","year":"2013","unstructured":"Al-Saidi NA, Akhtar M. Sarcomatoid renal cell carcinoma with rhabdoid features. Ann Saudi Med. 2013, 33:495-9. 10.5144\/0256-4947.2013.495","journal-title":"Ann Saudi Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2010.06.011","article-title":"Pediatric renal cell carcinoma","volume":"3","author":"Perlman EJ","year":"2010","unstructured":"Perlman EJ. Pediatric renal cell carcinoma. Surg Pathol Clin. 2010, 3:641-51. 10.1016\/j.path.2010.06.011","journal-title":"Surg Pathol Clin"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000002233","article-title":"Sarcomatoid and rhabdoid renal cell carcinoma: clinical, pathologic, and molecular genetic features","volume":"48","author":"Adeniran AJ","year":"2024","unstructured":"Adeniran AJ, Shuch B, Humphrey PA. Sarcomatoid and rhabdoid renal cell carcinoma: clinical, pathologic, and molecular genetic features. Am J Surg Pathol. 2024, 48:65-88. 10.1097\/pas.0000000000002233","journal-title":"Am J Surg Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10090642","article-title":"Retroperitoneal sarcomas: an update on the diagnostic pathology approach","volume":"10","author":"Choi JH","year":"2020","unstructured":"Choi JH, Ro JY. Retroperitoneal sarcomas: an update on the diagnostic pathology approach. Diagnostics (Basel). 2020, 10:642. 10.3390\/diagnostics10090642","journal-title":"Diagnostics (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2022.03.006","article-title":"Management of myxofibrosarcoma and undifferentiated pleomorphic sarcoma","volume":"31","author":"Crago AM","year":"2022","unstructured":"Crago AM, Cardona K, Kose\u0142a-Paterczyk H, Rutkowski P. Management of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Surg Oncol Clin N Am. 2022, 31:419-30. 10.1016\/j.soc.2022.03.006","journal-title":"Surg Oncol Clin N Am"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.30699\/IJP.2019.109242.2147","article-title":"Sarcomatoid chromophobe renal cell carcinoma with heterologous component","volume":"15","author":"Bharti S","year":"2020","unstructured":"Bharti S, Ram Choudhary G, Jyotsna Bharti N, Kumar Garg P, Arsha BS, Abhay Elhence P. Sarcomatoid chromophobe renal cell carcinoma with heterologous component. Iran J Pathol. 2020, 15:57-61. 10.30699\/IJP.2019.109242.2147","journal-title":"Iran J Pathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800451","article-title":"Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1","volume":"18","author":"Lewis JS","year":"2005","unstructured":"Lewis JS, Ritter JH, El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. Mod Pathol. 2005, 18:1471-81. 10.1038\/modpathol.3800451","journal-title":"Mod Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030422","article-title":"Renal cell carcinoma with sarcomatoid features: finally new therapeutic hope?","volume":"11","author":"Pichler R","year":"2019","unstructured":"Pichler R, Comp\u00e9rat E, Klatte T, Pichler M, Loidl W, Lusuardi L, Schmidinger M. Renal cell carcinoma with sarcomatoid features: finally new therapeutic hope?. Cancers (Basel). 2019, 11:422. 10.3390\/cancers11030422","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.049","article-title":"Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?","volume":"182","author":"Shuch B","year":"2009","unstructured":"Shuch B, Said J, La Rochelle JC, et al.. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?. J Urol. 2009, 182:2164-71. 10.1016\/j.juro.2009.07.049","journal-title":"J Urol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200103000-00001","article-title":"Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases","volume":"25","author":"de Peralta-Venturina M","year":"2001","unstructured":"de Peralta-Venturina M, Moch H, Amin M, et al.. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001, 25:275-84. 10.1097\/00000478-200103000-00001","journal-title":"Am J Surg Pathol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196809)22:3<545::aid-cncr2820220308>3.0.co;2-4","article-title":"Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults","volume":"22","author":"Farrow GM","year":"1968","unstructured":"Farrow GM, Harrison EG, Jr., Utz DC, ReMine WH. Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. Cancer. 1968, 22:3-545. 10.1002\/1097-0142(196809)22:3&lt;545::aid-cncr2820220308&gt;3.0.co;2-4","journal-title":"Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.176743","article-title":"Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma","volume":"9","author":"Kapur P","year":"2024","unstructured":"Kapur P, Zhong H, Le D, et al.. Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma. JCI Insight. 2024, 9:e176743. 10.1172\/jci.insight.176743","journal-title":"JCI Insight"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00779-w","article-title":"New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia","volume":"34","author":"Trpkov K","year":"2021","unstructured":"Trpkov K, Hes O, Williamson SR, et al.. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021, 34:1392-424. 10.1038\/s41379-021-00779-w","journal-title":"Mod Pathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46449","article-title":"Spindle cell renal neoplasms: a pathological case report on primary Renal leiomyosarcoma and sarcomatoid renal cell carcinoma","volume":"15","author":"Popov H","year":"2023","unstructured":"Popov H, Petkova L, Stoyanov GS. Spindle cell renal neoplasms: a pathological case report on primary Renal leiomyosarcoma and sarcomatoid renal cell carcinoma. Cureus. 2023, 15:e46449. 10.7759\/cureus.46449","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.88","article-title":"Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study","volume":"22","author":"Tong GX","year":"2009","unstructured":"Tong GX, Yu WM, Beaubier NT, Weeden EM, Hamele-Bena D, Mansukhani MM, O'Toole KM. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009, 22:1218-27. 10.1038\/modpathol.2009.88","journal-title":"Mod Pathol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0072-OA","article-title":"PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison","volume":"136","author":"Ozcan A","year":"2012","unstructured":"Ozcan A, de la Roza G, Ro JY, Shen SS, Truong LD. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison. Arch Pathol Lab Med. 2012, 136:1541-51. 10.5858\/arpa.2012-0072-OA","journal-title":"Arch Pathol Lab Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4161\/15384047.2014.956642","article-title":"Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications","volume":"15","author":"Miolo G","year":"2014","unstructured":"Miolo G, Ash A, Buonadonna A, et al.. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. Cancer Biol Ther. 2014, 15:1439-43. 10.4161\/15384047.2014.956642","journal-title":"Cancer Biol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200404000-00002","article-title":"Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome","volume":"28","author":"Cheville JC","year":"2004","unstructured":"Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004, 28:435-41. 10.1097\/00000478-200404000-00002","journal-title":"Am J Surg Pathol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002233","article-title":"Sarcomatoid and rhabdoid renal cell carcinoma: clinical, pathologic, and molecular genetic features","volume":"48","author":"Adeniran AJ","year":"2024","unstructured":"Adeniran AJ, Shuch B, Humphrey PA. Sarcomatoid and rhabdoid renal cell carcinoma: clinical, pathologic, and molecular genetic features. Am J Surg Pathol. 2024, 48:e65-88. 10.1097\/PAS.0000000000002233","journal-title":"Am J Surg Pathol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2020.101244","article-title":"Renal cell carcinoma with rhabdoid features: a rare aggressive and fatal variant","volume":"32","author":"Mohamed AH","year":"2020","unstructured":"Mohamed AH, Mohamud HA. Renal cell carcinoma with rhabdoid features: a rare aggressive and fatal variant. Urol Case Rep. 2020, 32:101244. 10.1016\/j.eucr.2020.101244","journal-title":"Urol Case Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100640","article-title":"The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma","volume":"33","author":"Hahn AW","year":"2022","unstructured":"Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun. 2022, 33:100640. 10.1016\/j.ctarc.2022.100640","journal-title":"Cancer Treat Res Commun"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000251","article-title":"Rhabdoid differentiation is associated with aggressive behavior in renal cell carcinoma: a clinicopathologic analysis of 76 cases with clinical follow-up","volume":"38","author":"Przybycin CG","year":"2014","unstructured":"Przybycin CG, McKenney JK, Reynolds JP, Campbell S, Zhou M, Karafa MT, Magi-Galluzzi C. Rhabdoid differentiation is associated with aggressive behavior in renal cell carcinoma: a clinicopathologic analysis of 76 cases with clinical follow-up. Am J Surg Pathol. 2014, 38:1260-5. 10.1097\/PAS.0000000000000251","journal-title":"Am J Surg Pathol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200010000-00002","article-title":"Renal cell carcinoma with rhabdoid features","volume":"24","author":"G\u00f6kden N","year":"2000","unstructured":"G\u00f6kden N, Nappi O, Swanson PE, Pfeifer JD, Vollmer RT, Wick MR, Humphrey PA. Renal cell carcinoma with rhabdoid features. Am J Surg Pathol. 2000, 24:1329-38. 10.1097\/00000478-200010000-00002","journal-title":"Am J Surg Pathol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028481","article-title":"Biphasic synovial sarcoma with a striking morphological divergence from the main mass to lymph node metastasis: a case report","volume":"101","author":"Woo HY","year":"2022","unstructured":"Woo HY. Biphasic synovial sarcoma with a striking morphological divergence from the main mass to lymph node metastasis: a case report. Medicine (Baltimore). 2022, 101:e28481. 10.1097\/MD.0000000000028481","journal-title":"Medicine (Baltimore)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2016.07.30","article-title":"Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components","volume":"5","author":"Manley BJ","year":"2016","unstructured":"Manley BJ, Hsieh JJ. Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components. Transl Cancer Res. 2016, 5:S160-5. 10.21037\/tcr.2016.07.30","journal-title":"Transl Cancer Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4103\/ccd.ccd_43_18","article-title":"Sarcomatoid carcinoma: a clinicopathological profile of two cases with diagnostic emphasis","volume":"9","author":"Urs AB","year":"2018","unstructured":"Urs AB, Kumar P, Uniyal A, Singh S, Gupta S. Sarcomatoid carcinoma: a clinicopathological profile of two cases with diagnostic emphasis. Contemp Clin Dent. 2018, 9:S164-7. 10.4103\/ccd.ccd_43_18","journal-title":"Contemp Clin Dent"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2304-3","article-title":"Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma","volume":"143","author":"Gu L","year":"2017","unstructured":"Gu L, Li H, Wang H, et al.. Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma. J Cancer Res Clin Oncol. 2017, 143:499-508. 10.1007\/s00432-016-2304-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.47162\/RJME.62.3.22","article-title":"Sarcomatoid renal cell carcinoma with clear cells and eosinophilia: a case report and short review of the literature","volume":"62","author":"Ne\u015fiu A","year":"2021","unstructured":"Ne\u015fiu A, Neam\u0163u C, Nicolescu CM, et al.. Sarcomatoid renal cell carcinoma with clear cells and eosinophilia: a case report and short review of the literature. Rom J Morphol Embryol. 2021, 62:835-9. 10.47162\/RJME.62.3.22","journal-title":"Rom J Morphol Embryol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/his.13362","article-title":"Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases","volume":"72","author":"Perrino CM","year":"2018","unstructured":"Perrino CM, Grignon DJ, Williamson SR, Idrees MT, Eble JN, Cheng L. Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases. Histopathology. 2018, 72:305-19. 10.1111\/his.13362","journal-title":"Histopathology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.2020.134","article-title":"Histologic heterogeneity of extirpated renal cell carcinoma specimens: implications for renal mass biopsy","volume":"7","author":"Nahouraii LM","year":"2020","unstructured":"Nahouraii LM, Allen JL, Merrill SB, Lehman E, Kaag MG, Raman JD. Histologic heterogeneity of extirpated renal cell carcinoma specimens: implications for renal mass biopsy. J Kidney Cancer VHL. 2020, 7:20-5. 10.15586\/jkcvhl.2020.134","journal-title":"J Kidney Cancer VHL"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30314","article-title":"Renal cancer subtypes: should we be lumping or splitting for therapeutic decision making?","volume":"123","author":"Haake SM","year":"2017","unstructured":"Haake SM, Rathmell WK. Renal cancer subtypes: should we be lumping or splitting for therapeutic decision making?. Cancer. 2017, 123:200-9. 10.1002\/cncr.30314","journal-title":"Cancer"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1590\/0100-3984.2013.1927","article-title":"Renal cell carcinoma: histological classification and correlation with imaging findings","volume":"48","author":"Muglia VF","year":"2015","unstructured":"Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015, 48:166-74. 10.1590\/0100-3984.2013.1927","journal-title":"Radiol Bras"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2014.55.10.690","article-title":"Unclassified mucinous renal cell carcinoma: a rare histopathological entity","volume":"55","author":"Raheem OA","year":"2014","unstructured":"Raheem OA, Godebu E, Cohen SA, Shabaik A, Parsons JK. Unclassified mucinous renal cell carcinoma: a rare histopathological entity. Korean J Urol. 2014, 55:690-2. 10.4111\/kju.2014.55.10.690","journal-title":"Korean J Urol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2013-0653-RA","article-title":"Diagnostic approach to eosinophilic renal neoplasms","volume":"138","author":"Kryvenko ON","year":"2014","unstructured":"Kryvenko ON, Jorda M, Argani P, Epstein JI. Diagnostic approach to eosinophilic renal neoplasms. Arch Pathol Lab Med. 2014, 138:1531-41. 10.5858\/arpa.2013-0653-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-015-0402-1","article-title":"Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects","volume":"10","author":"Zhao M","year":"2015","unstructured":"Zhao M, He XL, Teng XD. Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects. Diagn Pathol. 2015, 10:168. 10.1186\/s13000-015-0402-1","journal-title":"Diagn Pathol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58470","article-title":"The WHO 2022 classification of renal neoplasms (5th edition): salient updates","volume":"16","author":"Goswami PR","year":"2024","unstructured":"Goswami PR, Singh G, Patel T, Dave R. The WHO 2022 classification of renal neoplasms (5th edition): salient updates. Cureus. 2024, 16:e58470. 10.7759\/cureus.58470","journal-title":"Cureus"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182635954","article-title":"Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship","volume":"36","author":"Gupta R","year":"2012","unstructured":"Gupta R, Billis A, Shah RB, et al.. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol. 2012, 36:1265-78. 10.1097\/PAS.0b013e3182635954","journal-title":"Am J Surg Pathol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040108","article-title":"Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site","volume":"10","author":"Selves J","year":"2018","unstructured":"Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ili\u00e9 M. Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers (Basel). 2018, 10:108. 10.3390\/cancers10040108","journal-title":"Cancers (Basel)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s44178-024-00071-2","article-title":"Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma","volume":"3","author":"Shen Y","year":"2024","unstructured":"Shen Y, Liu Z, Wei Q, Xue W. Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma. Holist Integr Oncol. 2024, 3:7. 10.1007\/s44178-024-00071-2","journal-title":"Holist Integr Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4693","article-title":"Translocation carcinomas of the kidney after chemotherapy in childhood","volume":"24","author":"Argani P","year":"2006","unstructured":"Argani P, La\u00e9 M, Ballard ET, et al.. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006, 24:1529-34. 10.1200\/JCO.2005.04.4693","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/his.13395","article-title":"Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients","volume":"72","author":"Li Y","year":"2018","unstructured":"Li Y, Reuter VE, Matoso A, Netto GJ, Epstein JI, Argani P. Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients. Histopathology. 2018, 72:588-600. 10.1111\/his.13395","journal-title":"Histopathology"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001111","article-title":"Eosinophilic solid and cystic (ESC) renal cell carcinomas Harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum","volume":"42","author":"Palsgrove DN","year":"2018","unstructured":"Palsgrove DN, Li Y, Pratilas CA, et al.. Eosinophilic solid and cystic (ESC) renal cell carcinomas Harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol. 2018, 42:1166-81. 10.1097\/PAS.0000000000001111","journal-title":"Am J Surg Pathol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2014.5037","article-title":"Renal cell carcinoma with rhabdoid and sarcomatoid features presented as a metastatic thigh mass with an unusual immunohistochemical profile","volume":"6","author":"Abdou AG","year":"2014","unstructured":"Abdou AG, Kandil M, Elshakhs S, El-Dien MS, Abdallah R. Renal cell carcinoma with rhabdoid and sarcomatoid features presented as a metastatic thigh mass with an unusual immunohistochemical profile. Rare Tumors. 2014, 6:5037. 10.4081\/rt.2014.5037","journal-title":"Rare Tumors"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.01.005","article-title":"Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy","volume":"34","author":"Nguyen DP","year":"2016","unstructured":"Nguyen DP, Vertosick EA, Corradi RB, et al.. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urol Oncol. 2016, 34:259.e1-8. 10.1016\/j.urolonc.2016.01.005","journal-title":"Urol Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01108-5","article-title":"Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis","volume":"35","author":"Amin MB","year":"2022","unstructured":"Amin MB, McKenney JK, Martignoni G, Campbell SC, Pal S, Tickoo SK. Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis. Mod Pathol. 2022, 35:1306-16. 10.1038\/s41379-022-01108-5","journal-title":"Mod Pathol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.74984","article-title":"Unclassifiable renal cell carcinoma with an estimated 100% sarcomatoid component: a case report","volume":"16","author":"Bekhakh C","year":"2024","unstructured":"Bekhakh C, Haloui A, Akouh N, Nassira K, Bennani A. Unclassifiable renal cell carcinoma with an estimated 100% sarcomatoid component: a case report. Cureus. 2024, 16:e74984. 10.7759\/cureus.74984","journal-title":"Cureus"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/BF02552254","article-title":"Sarcomatoid renal cell carcinoma: an immunohistochemical and ultrastructural study","volume":"25","author":"Morikawa Y","year":"1993","unstructured":"Morikawa Y, Tohya K, Kusuyama Y, Masui M, Wakasugi C. Sarcomatoid renal cell carcinoma: an immunohistochemical and ultrastructural study. Int Urol Nephrol. 1993, 25:51-8. 10.1007\/BF02552254","journal-title":"Int Urol Nephrol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny Z","year":"2021","unstructured":"Bakouny Z, Braun DA, Shukla SA, et al.. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021, 12:808. 10.1038\/s41467-021-21068-9","journal-title":"Nat Commun"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.3","article-title":"PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study","volume":"24","author":"Ozcan A","year":"2011","unstructured":"Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, Truong LD. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011, 24:751-64. 10.1038\/modpathol.2011.3","journal-title":"Mod Pathol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.12.012","article-title":"Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma","volume":"44","author":"Chang A","year":"2013","unstructured":"Chang A, Brimo F, Montgomery EA, Epstein JI. Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma. Hum Pathol. 2013, 44:1563-8. 10.1016\/j.humpath.2012.12.012","journal-title":"Hum Pathol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-011-0735-1","article-title":"Vimentin in cancer and its potential as a molecular target for cancer therapy","volume":"68","author":"Satelli A","year":"2011","unstructured":"Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011, 68:3033-46. 10.1007\/s00018-011-0735-1","journal-title":"Cell Mol Life Sci"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1177\/2632010X19848005","article-title":"A case of sarcomatoid renal cell carcinoma with osseous metaplasia and papillary renal cell carcinoma metastasis","volume":"12","author":"Zhang H","year":"2019","unstructured":"Zhang H, Majeed NK, Sharifi R, Guzman G. A case of sarcomatoid renal cell carcinoma with osseous metaplasia and papillary renal cell carcinoma metastasis. Clin Pathol. 2019, 12:2632010X19848005. 10.1177\/2632010X19848005","journal-title":"Clin Pathol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318299f12e","article-title":"Renal tumors: diagnostic and prognostic biomarkers","volume":"37","author":"Tan PH","year":"2013","unstructured":"Tan PH, Cheng L, Rioux-Leclercq N, et al.. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol. 2013, 37:1518-31. 10.1097\/PAS.0b013e318299f12e","journal-title":"Am J Surg Pathol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2021.11.010","article-title":"Chromophobe renal cell carcinoma: novel molecular insights and clinicopathologic updates","volume":"9","author":"Alaghehbandan R","year":"2022","unstructured":"Alaghehbandan R, Przybycin CG, Verkarre V, Mehra R. Chromophobe renal cell carcinoma: novel molecular insights and clinicopathologic updates. Asian J Urol. 2022, 9:1-11. 10.1016\/j.ajur.2021.11.010","journal-title":"Asian J Urol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1987.tb02659.x","article-title":"Expression of epithelial markers in sarcomatoid carcinoma: an immunohistochemical study","volume":"11","author":"Ogawa K","year":"1987","unstructured":"Ogawa K, Kim YC, Nakashima Y, Yamabe H, Takeda T, Hamashima Y. Expression of epithelial markers in sarcomatoid carcinoma: an immunohistochemical study. Histopathology. 1987, 11:511-22. 10.1111\/j.1365-2559.1987.tb02659.x","journal-title":"Histopathology"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation","volume":"3","author":"Joseph RW","year":"2015","unstructured":"Joseph RW, Millis SZ, Carballido EM, et al.. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer Immunol Res. 2015, 3:1303-7. 10.1158\/2326-6066.CIR-15-0150","journal-title":"Cancer Immunol Res"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang Q","year":"2022","unstructured":"Tang Q, Chen Y, Li X, et al.. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022, 13:964442. 10.3389\/fimmu.2022.964442","journal-title":"Front Immunol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S176242","article-title":"Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma","volume":"10","author":"Wang Z","year":"2018","unstructured":"Wang Z, Zeng X, Chen R, Chen Z. Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma. Cancer Manag Res. 2018, 10:5339-47. 10.2147\/CMAR.S176242","journal-title":"Cancer Manag Res"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.1000-9604.2016.01.03","article-title":"Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas","volume":"28","author":"Rao Q","year":"2016","unstructured":"Rao Q, Xia QY, Cheng L, Zhou XJ. Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas. Chin J Cancer Res. 2016, 28:29-49. 10.3978\/j.issn.1000-9604.2016.01.03","journal-title":"Chin J Cancer Res"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202259","article-title":"PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?","volume":"68","author":"Barr ML","year":"2015","unstructured":"Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B. PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?. J Clin Pathol. 2015, 68:12-7. 10.1136\/jclinpath-2014-202259","journal-title":"J Clin Pathol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.4103\/UA.UA_131_18","article-title":"Differentiation of renal cell tumors with morphological cocktails using a minimal panel of immunohistochemical markers","volume":"12","author":"Rao BV","year":"2020","unstructured":"Rao BV, Regulavalasa T, Fonseca D, et al.. Differentiation of renal cell tumors with morphological cocktails using a minimal panel of immunohistochemical markers. Urol Ann. 2020, 12:236-40. 10.4103\/UA.UA_131_18","journal-title":"Urol Ann"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147649","article-title":"MiTF\/TFE translocation renal cell carcinomas: from clinical entities to molecular insights","volume":"23","author":"Simonaggio A","year":"2022","unstructured":"Simonaggio A, Ambrosetti D, Verkarre V, Auvray M, Oudard S, Vano YA. MiTF\/TFE translocation renal cell carcinomas: from clinical entities to molecular insights. Int J Mol Sci. 2022, 23:7649. 10.3390\/ijms23147649","journal-title":"Int J Mol Sci"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23007","article-title":"Translocation carcinomas of the kidney","volume":"61","author":"Argani P","year":"2022","unstructured":"Argani P. Translocation carcinomas of the kidney. Genes Chromosom Cancer. 2022, 61:219-27. 10.1002\/gcc.23007","journal-title":"Genes Chromosom Cancer"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3389\/fruro.2025.1582675","article-title":"Unclassifiable renal carcinoma with medullary phenotype and SMARCB1 deficiency: case report","volume":"5","author":"Mehanna SH","year":"2025","unstructured":"Mehanna SH, Ronkoski TG, Machado C, Wolff LS, Cavalli AC, Hota T, Koleski FC. Unclassifiable renal carcinoma with medullary phenotype and SMARCB1 deficiency: case report. Front Urol. 2025, 5:1582675. 10.3389\/fruro.2025.1582675","journal-title":"Front Urol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.86","article-title":"Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma","volume":"28","author":"Williamson SR","year":"2015","unstructured":"Williamson SR, Eble JN, Amin MB, et al.. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol. 2015, 28:80-94. 10.1038\/modpathol.2014.86","journal-title":"Mod Pathol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0017-7","article-title":"Pattern multiplicity and fumarate hydratase (FH)\/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration","volume":"31","author":"Muller M","year":"2018","unstructured":"Muller M, Guillaud-Bataille M, Salleron J, et al.. Pattern multiplicity and fumarate hydratase (FH)\/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Mod Pathol. 2018, 31:974-83. 10.1038\/s41379-018-0017-7","journal-title":"Mod Pathol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13131","article-title":"Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets","volume":"7","author":"Chen YB","year":"2016","unstructured":"Chen YB, Xu J, Skanderup AJ, et al.. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun. 2016, 7:13131. 10.1038\/ncomms13131","journal-title":"Nat Commun"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030602","article-title":"Comprehensive immunoprofiles of renal cell carcinoma subtypes","volume":"12","author":"Kim M","year":"2020","unstructured":"Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH. Comprehensive immunoprofiles of renal cell carcinoma subtypes. Cancers (Basel). 2020, 12:602. 10.3390\/cancers12030602","journal-title":"Cancers (Basel)"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3275-8","article-title":"Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases","volume":"17","author":"Yu W","year":"2017","unstructured":"Yu W, Wang Y, Jiang Y, Zhang W, Li Y. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases. BMC Cancer. 2017, 17:293. 10.1186\/s12885-017-3275-8","journal-title":"BMC Cancer"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194985","article-title":"Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis","volume":"13","author":"Usman S","year":"2021","unstructured":"Usman S, Waseem NH, Nguyen TK, Mohsin S, Jamal A, Teh MT, Waseem A. Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers (Basel). 2021, 13:4985. 10.3390\/cancers13194985","journal-title":"Cancers (Basel)"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1111\/his.12298","article-title":"Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers","volume":"64","author":"Miettinen M","year":"2014","unstructured":"Miettinen M. Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers. Histopathology. 2014, 64:101-18. 10.1111\/his.12298","journal-title":"Histopathology"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1177\/10668969231215819","article-title":"Loss of histone H3K27 trimethylation (H3K27me3) expression as a potential diagnostic pitfall in sarcomatoid carcinoma","volume":"32","author":"Zilla ML","year":"2024","unstructured":"Zilla ML, John I, Naous R. Loss of histone H3K27 trimethylation (H3K27me3) expression as a potential diagnostic pitfall in sarcomatoid carcinoma. Int J Surg Pathol. 2024, 32:1089-94. 10.1177\/10668969231215819","journal-title":"Int J Surg Pathol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1057","article-title":"Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape","volume":"23","author":"Wang Z","year":"2017","unstructured":"Wang Z, Kim TB, Peng B, et al.. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape. Clin Cancer Res. 2017, 23:6686-96. 10.1158\/1078-0432.CCR-17-1057","journal-title":"Clin Cancer Res"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier M","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010, 2:a001008. 10.1101\/cshperspect.a001008","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref86","article-title":"p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase","volume":"88","author":"Brusa G","year":"2003","unstructured":"Brusa G, Benvenuti M, Mazzacurati L, et al.. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase. Haematologica. 2003, 88:622-30.","journal-title":"Haematologica"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800739","article-title":"Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma","volume":"20","author":"Brunelli M","year":"2007","unstructured":"Brunelli M, Gobbo S, Cossu-Rocca P, et al.. Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. Mod Pathol. 2007, 20:303-9. 10.1038\/modpathol.3800739","journal-title":"Mod Pathol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0787","article-title":"Targeting the RB-pathway in cancer therapy","volume":"16","author":"Knudsen ES","year":"2010","unstructured":"Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res. 2010, 16:1094-9. 10.1158\/1078-0432.CCR-09-0787","journal-title":"Clin Cancer Res"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2024.e00410","article-title":"Genetic study of the CDKN2A and CDKN2B genes in renal cell carcinoma patients","volume":"40","author":"Kiatprungvech N","year":"2024","unstructured":"Kiatprungvech N, Sangkum P, Malinee R, et al.. Genetic study of the CDKN2A and CDKN2B genes in renal cell carcinoma patients. Pract Lab Med. 2024, 40:e00410. 10.1016\/j.plabm.2024.e00410","journal-title":"Pract Lab Med"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189795","article-title":"Loss of von Hippel-Lindau (VHL) tumor suppressor gene function: VHL-HIF pathway and advances in treatments for metastatic renal cell carcinoma (RCC)","volume":"22","author":"Kim H","year":"2021","unstructured":"Kim H, Shim BY, Lee SJ, Lee JY, Lee HJ, Kim IH. Loss of von Hippel-Lindau (VHL) tumor suppressor gene function: VHL-HIF pathway and advances in treatments for metastatic renal cell carcinoma (RCC). Int J Mol Sci. 2021, 22:9795. 10.3390\/ijms22189795","journal-title":"Int J Mol Sci"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear cell renal cell carcinoma ontogeny and mechanisms of lethality","volume":"17","author":"Jonasch E","year":"2021","unstructured":"Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021, 17:245-61. 10.1038\/s41581-020-00359-2","journal-title":"Nat Rev Nephrol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3182a102d1","article-title":"PBRM1 and BAP1 as novel targets for renal cell carcinoma","volume":"19","author":"Brugarolas J","year":"2013","unstructured":"Brugarolas J. PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J. 2013, 19:324-32. 10.1097\/PPO.0b013e3182a102d1","journal-title":"Cancer J"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010064","article-title":"Role of NF2 mutation in the development of eleven different cancers","volume":"17","author":"Nouri SH","year":"2024","unstructured":"Nouri SH, Nitturi V, Ledbetter E, English CW, Lau S, Klisch TJ, Patel AJ. Role of NF2 mutation in the development of eleven different cancers. Cancers (Basel). 2024, 17:10.3390\/cancers17010064","journal-title":"Cancers (Basel)"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172744","article-title":"Molecular and clinicopathological profiling of clear cell renal cell carcinoma with rhabdoid features: an integrative pathway-based stratification approach","volume":"17","author":"Lu Z","year":"2025","unstructured":"Lu Z, Zhao Q, Xu H, Katz MH, Wang DS, Andry CD, Yang S. Molecular and clinicopathological profiling of clear cell renal cell carcinoma with rhabdoid features: an integrative pathway-based stratification approach. Cancers (Basel). 2025, 17:2744. 10.3390\/cancers17172744","journal-title":"Cancers (Basel)"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1606639","article-title":"Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors","volume":"8","author":"Hanif A","year":"2019","unstructured":"Hanif A, Pandey M, Khan S, Attwood K, George S. Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors. Oncoimmunology. 2019, 8:1606639. 10.1080\/2162402X.2019.1606639","journal-title":"Oncoimmunology"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00607-9","article-title":"Whole exome and transcriptome sequencing reveal clonal evolution and exhibit immune-related features in metastatic colorectal tumors","volume":"7","author":"Li C","year":"2021","unstructured":"Li C, Xu J, Wang X, et al.. Whole exome and transcriptome sequencing reveal clonal evolution and exhibit immune-related features in metastatic colorectal tumors. Cell Death Discov. 2021, 7:222. 10.1038\/s41420-021-00607-9","journal-title":"Cell Death Discov"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24112","article-title":"Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers","volume":"9","author":"Sourbier C","year":"2018","unstructured":"Sourbier C, Liao PJ, Ricketts CJ, et al.. Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. Oncotarget. 2018, 9:10723-33. 10.18632\/oncotarget.24112","journal-title":"Oncotarget"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00357-x","article-title":"The language of chromatin modification in human cancers","volume":"21","author":"Zhao S","year":"2021","unstructured":"Zhao S, Allis CD, Wang GG. The language of chromatin modification in human cancers. Nat Rev Cancer. 2021, 21:413-30. 10.1038\/s41568-021-00357-x","journal-title":"Nat Rev Cancer"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020322","article-title":"TSC\/mTOR pathway mutation associated eosinophilic\/oncocytic renal neoplasms: a heterogeneous group of tumors with distinct morphology, immunohistochemical profile, and similar genetic background","volume":"10","author":"Pivovarcikova K","year":"2022","unstructured":"Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O. TSC\/mTOR pathway mutation associated eosinophilic\/oncocytic renal neoplasms: a heterogeneous group of tumors with distinct morphology, immunohistochemical profile, and similar genetic background. Biomedicines. 2022, 10:322. 10.3390\/biomedicines10020322","journal-title":"Biomedicines"},{"key":"ref100","article-title":"Clear cell renal cell carcinoma with BAP1 mutation: a report of two cases","volume":"11","author":"Lee J","year":"2023","unstructured":"Lee J, Thuzar M, DiPoto-Brahmbhatt AC, et al.. Clear cell renal cell carcinoma with BAP1 mutation: a report of two cases. Am J Clin Exp Urol. 2023, 11:429-34.","journal-title":"Am J Clin Exp Urol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70465","article-title":"Unravelling the distinct effects of VHL mutations and chromosome 3p loss in clear cell renal cell carcinoma: implications for prognosis and treatment","volume":"15","author":"Wang X","year":"2025","unstructured":"Wang X, Li JR, Chowdhury NR, Wu L, Chao C. Unravelling the distinct effects of VHL mutations and chromosome 3p loss in clear cell renal cell carcinoma: implications for prognosis and treatment. Clin Transl Med. 2025, 15:e70465. 10.1002\/ctm2.70465","journal-title":"Clin Transl Med"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241298500","article-title":"Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective","volume":"16","author":"Pezzicoli G","year":"2024","unstructured":"Pezzicoli G, Musci V, Ciciriello F, et al.. Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective. Ther Adv Med Oncol. 2024, 16:17588359241298500. 10.1177\/17588359241298500","journal-title":"Ther Adv Med Oncol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042366","article-title":"NTRK therapy among different types of cancers, review and future perspectives","volume":"25","author":"Theik NW","year":"2024","unstructured":"Theik NW, Muminovic M, Alvarez-Pinzon AM, Shoreibah A, Hussein AM, Raez LE. NTRK therapy among different types of cancers, review and future perspectives. Int J Mol Sci. 2024, 25:2366. 10.3390\/ijms25042366","journal-title":"Int J Mol Sci"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193396","article-title":"TFE3-rearranged tumors of the kidney: an emerging conundrum","volume":"16","author":"Cali\u00f2 A","year":"2024","unstructured":"Cali\u00f2 A, Marletta S, Brunelli M, et al.. TFE3-rearranged tumors of the kidney: an emerging conundrum. Cancers (Basel). 2024, 16:3396. 10.3390\/cancers16193396","journal-title":"Cancers (Basel)"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)64549-1","article-title":"Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype","volume":"168","author":"Zisman A","year":"2002","unstructured":"Zisman A, Chao DH, Pantuck AJ, et al.. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol. 2002, 168:950-5. 10.1016\/s0022-5347(05)64549-1","journal-title":"J Urol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2019.12.004","article-title":"The therapeutic landscape of renal cell carcinoma: from the dark age to the golden age","volume":"40","author":"Huang JJ","year":"2020","unstructured":"Huang JJ, Hsieh JJ. The therapeutic landscape of renal cell carcinoma: from the dark age to the golden age. Semin Nephrol. 2020, 40:28-41. 10.1016\/j.semnephrol.2019.12.004","journal-title":"Semin Nephrol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1525735113","article-title":"Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma","volume":"113","author":"Bi M","year":"2016","unstructured":"Bi M, Zhao S, Said JW, et al.. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci. 2016, 113:2170-5. 10.1073\/pnas.1525735113","journal-title":"Proc Natl Acad Sci"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.2018.99","article-title":"Extensive metastatic sarcomatoid renal cell carcinoma evaluated by (18)f-FDG PET\/CT: a case report and review of literature","volume":"5","author":"Fuser D","year":"2018","unstructured":"Fuser D, Hedberg ML, Dehner LP, Dehdashti F, Siegel BA. Extensive metastatic sarcomatoid renal cell carcinoma evaluated by (18)f-FDG PET\/CT: a case report and review of literature. J Kidney Cancer VHL. 2018, 5:1-6. 10.15586\/jkcvhl.2018.99","journal-title":"J Kidney Cancer VHL"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16125","article-title":"Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study","volume":"133","author":"Blum KA","year":"2024","unstructured":"Blum KA, Silagy AW, Knezevic A, et al.. Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study. BJU Int. 2024, 133:169-78. 10.1111\/bju.16125","journal-title":"BJU Int"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.09.004","article-title":"Outcomes of patients with advanced renal cell carcinoma with non-clear cell histology treated with systemic therapy","volume":"21","author":"Urman D","year":"2023","unstructured":"Urman D, Deshler L, Weise N, et al.. Outcomes of patients with advanced renal cell carcinoma with non-clear cell histology treated with systemic therapy. Clin Genitourin Cancer. 2023, 21:660-8.e1. 10.1016\/j.clgc.2023.09.004","journal-title":"Clin Genitourin Cancer"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae333","article-title":"Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience","volume":"30","author":"Fuentes HE","year":"2025","unstructured":"Fuentes HE, Suleiman R, Graham RP, Villasboas Bisneto JC, Garcia JJ, Halfdanarson TR. Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience. Oncologist. 2025, 30:oyae333. 10.1093\/oncolo\/oyae333","journal-title":"Oncologist"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.694","article-title":"Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies","volume":"5","author":"Ou X","year":"2024","unstructured":"Ou X, Gao G, Habaz IA, Wang Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm (2020). 2024, 5:e694. 10.1002\/mco2.694","journal-title":"MedComm (2020)"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020326","article-title":"Immune-based and novel therapies in variant histology renal cell carcinomas","volume":"17","author":"Miller JW","year":"2025","unstructured":"Miller JW, Johnson JS, Guske C, et al.. Immune-based and novel therapies in variant histology renal cell carcinomas. Cancers (Basel). 2025, 17:326. 10.3390\/cancers17020326","journal-title":"Cancers (Basel)"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts CJ","year":"2018","unstructured":"Ricketts CJ, De Cubas AA, Fan H, et al.. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018, 23:313-26.e5. 10.1016\/j.celrep.2018.03.075","journal-title":"Cell Rep"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S526583","article-title":"Clinicopathological features and prognostic factors of renal cell carcinoma in young patients under 45 years: a single-center retrospective study","volume":"17","author":"Gao Y","year":"2025","unstructured":"Gao Y, Yan H, Zhang T, Lu G, Ma L. Clinicopathological features and prognostic factors of renal cell carcinoma in young patients under 45 years: a single-center retrospective study. Cancer Manag Res. 2025, 17:1233-42. 10.2147\/CMAR.S526583","journal-title":"Cancer Manag Res"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193408","article-title":"Planned and unplanned sarcoma resections: comparative analysis of local recurrence, metastasis, and mortality","volume":"16","author":"Nydegger KN","year":"2024","unstructured":"Nydegger KN, Obergfell TT, Heesen P, Schelling G, Studer G, Bode-Lesniewska B, Fuchs B. Planned and unplanned sarcoma resections: comparative analysis of local recurrence, metastasis, and mortality. Cancers (Basel). 2024, 16:3408. 10.3390\/cancers16193408","journal-title":"Cancers (Basel)"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023717","article-title":"Renal cell carcinoma in children and adolescents: single-center experience and literature review","volume":"100","author":"He M","year":"2021","unstructured":"He M, Cai J, Zhu K, et al.. Renal cell carcinoma in children and adolescents: single-center experience and literature review. Medicine (Baltimore). 2021, 100:e23717. 10.1097\/MD.0000000000023717","journal-title":"Medicine (Baltimore)"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9090111","article-title":"Translocation renal cell carcinoma: an update on clinicopathological and molecular features","volume":"9","author":"Inamura K","year":"2017","unstructured":"Inamura K. Translocation renal cell carcinoma: an update on clinicopathological and molecular features. Cancers (Basel). 2017, 9:111. 10.3390\/cancers9090111","journal-title":"Cancers (Basel)"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2024.114371","article-title":"Development and evaluation of pediatric acute care hospital referral regions in eight states","volume":"276","author":"Joseph AM","year":"2025","unstructured":"Joseph AM, Minturn JS, Kurland KS, Davis BS, Kahn JM. Development and evaluation of pediatric acute care hospital referral regions in eight states. J Pediatr. 2025, 276:114371. 10.1016\/j.jpeds.2024.114371","journal-title":"J Pediatr"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3181f47aa4","article-title":"Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease","volume":"34","author":"Molina AM","year":"2011","unstructured":"Molina AM, Tickoo SK, Ishill N, et al.. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol. 2011, 34:454-9. 10.1097\/COC.0b013e3181f47aa4","journal-title":"Am J Clin Oncol"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.3233\/kca-210126","article-title":"Sarcomatoid renal cell carcinoma: the present and future of treatment paradigms","volume":"5","author":"Candelario N","year":"2021","unstructured":"Candelario N, Geiger C, Flaig T. Sarcomatoid renal cell carcinoma: the present and future of treatment paradigms. Kidney Cancer. 2021, 5:167-79. 10.3233\/kca-210126","journal-title":"Kidney Cancer"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir NM","year":"2024","unstructured":"Tannir NM, Albig\u00e8s L, McDermott DF, et al.. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024, 35:1026-38. 10.1016\/j.annonc.2024.07.727","journal-title":"Ann Oncol"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et al.. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021, 384:829-41. 10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70144","article-title":"Current evidences and future perspectives in the management of metastatic non-clear cell renal cell carcinoma","volume":"32","author":"Nakanishi S","year":"2025","unstructured":"Nakanishi S, Inokuchi J. Current evidences and future perspectives in the management of metastatic non-clear cell renal cell carcinoma. Int J Urol. 2025, 32:1118-28. 10.1111\/iju.70144","journal-title":"Int J Urol"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong AJ","year":"2016","unstructured":"Armstrong AJ, Halabi S, Eisen T, et al.. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016, 17:378-88. 10.1016\/S1470-2045(15)00515-X","journal-title":"Lancet Oncol"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.941835","article-title":"The role of immunotherapy in non-clear cell renal cell carcinoma","volume":"13","author":"Climent C","year":"2023","unstructured":"Climent C, Soriano S, Bonfill T, et al.. The role of immunotherapy in non-clear cell renal cell carcinoma. Front Oncol. 2023, 13:941835. 10.3389\/fonc.2023.941835","journal-title":"Front Oncol"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0028","article-title":"Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions","volume":"8","author":"Zibelman M","year":"2016","unstructured":"Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy. 2016, 8:785-98. 10.2217\/imt-2016-0028","journal-title":"Immunotherapy"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000721","article-title":"A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma","volume":"33","author":"Patel HV","year":"2021","unstructured":"Patel HV, Srivastava A, Srinivasan R, Singer EA. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma. Curr Opin Oncol. 2021, 33:212-20. 10.1097\/CCO.0000000000000721","journal-title":"Curr Opin Oncol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2372","article-title":"Facts and hopes for immunotherapy in renal cell carcinoma","volume":"28","author":"Yao C","year":"2022","unstructured":"Yao C, Zhang T, Wu T, Brugarolas J. Facts and hopes for immunotherapy in renal cell carcinoma. Clin Cancer Res. 2022, 28:5013-20. 10.1158\/1078-0432.CCR-21-2372","journal-title":"Clin Cancer Res"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32040230","article-title":"LAG3, TIM3 and TIGIT: new targets for immunotherapy and potential associations with radiotherapy","volume":"32","author":"Mire\u0219tean CC","year":"2025","unstructured":"Mire\u0219tean CC, Iancu RI, Iancu DP. LAG3, TIM3 and TIGIT: new targets for immunotherapy and potential associations with radiotherapy. Curr Oncol. 2025, 32:230. 10.3390\/curroncol32040230","journal-title":"Curr Oncol"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000307","article-title":"Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact","volume":"26","author":"Manley BJ","year":"2016","unstructured":"Manley BJ, Hakimi AA. Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol. 2016, 26:383-7. 10.1097\/MOU.0000000000000307","journal-title":"Curr Opin Urol"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2631","article-title":"Mutations in TSC1, TSC2, and mTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma","volume":"22","author":"Kwiatkowski DJ","year":"2016","unstructured":"Kwiatkowski DJ, Choueiri TK, Fay AP, et al.. Mutations in TSC1, TSC2, and mTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2016, 22:2445-52. 10.1158\/1078-0432.CCR-15-2631","journal-title":"Clin Cancer Res"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.21037\/tp-24-35","article-title":"Treatment of metastatic TFE3 microphthalmia transcription factor translocation renal cell carcinoma: a case report","volume":"13","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Li C, Deng X, et al.. Treatment of metastatic TFE3 microphthalmia transcription factor translocation renal cell carcinoma: a case report. Transl Pediatr. 2024, 13:499-507. 10.21037\/tp-24-35","journal-title":"Transl Pediatr"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00349","article-title":"Clinical utility of genomic testing in cancer care","volume":"6","author":"Pritchard D","year":"2022","unstructured":"Pritchard D, Goodman C, Nadauld LD. Clinical utility of genomic testing in cancer care. JCO Precis Oncol. 2022, 6:e2100349. 10.1200\/PO.21.00349","journal-title":"JCO Precis Oncol"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.12.006","article-title":"Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific evolutionary subtypes in clear cell renal cell carcinoma","volume":"21","author":"Bihr S","year":"2019","unstructured":"Bihr S, Ohashi R, Moore AL, et al.. Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific evolutionary subtypes in clear cell renal cell carcinoma. Neoplasia. 2019, 21:247-56. 10.1016\/j.neo.2018.12.006","journal-title":"Neoplasia"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051087","article-title":"Molecular diagnostic review of diffuse large B-cell lymphoma and its tumor microenvironment","volume":"12","author":"Ta R","year":"2022","unstructured":"Ta R, Yang D, Hirt C, Drago T, Flavin R. Molecular diagnostic review of diffuse large B-cell lymphoma and its tumor microenvironment. Diagnostics (Basel). 2022, 12:1087. 10.3390\/diagnostics12051087","journal-title":"Diagnostics (Basel)"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00419","article-title":"Clinical review on the management of metastatic renal cell carcinoma","volume":"18","author":"Tran J","year":"2022","unstructured":"Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract. 2022, 18:187-96. 10.1200\/OP.21.00419","journal-title":"JCO Oncol Pract"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001476","article-title":"Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer","volume":"44","author":"Williamson SR","year":"2020","unstructured":"Williamson SR, Gill AJ, Argani P, et al.. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer. Am J Surg Pathol. 2020, 44:e47-65. 10.1097\/PAS.0000000000001476","journal-title":"Am J Surg Pathol"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.02.003","article-title":"The new WHO category of \"molecularly defined renal carcinomas\": clinical and diagnostic features and management implications","volume":"42","author":"Kanakaraj J","year":"2024","unstructured":"Kanakaraj J, Chang J, Hampton LJ, Smith SC. The new WHO category of \"molecularly defined renal carcinomas\": clinical and diagnostic features and management implications. Urol Oncol. 2024, 42:211-9. 10.1016\/j.urolonc.2024.02.003","journal-title":"Urol Oncol"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.04.011","article-title":"Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation","volume":"33","author":"Adibi M","year":"2015","unstructured":"Adibi M, Thomas AZ, Borregales LD, et al.. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015, 33:427.e17-23. 10.1016\/j.urolonc.2015.04.011","journal-title":"Urol Oncol"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114350","article-title":"Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma","volume":"43","author":"El Zarif T","year":"2024","unstructured":"El Zarif T, Semaan K, Eid M, et al.. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. Cell Rep. 2024, 43:114350. 10.1016\/j.celrep.2024.114350","journal-title":"Cell Rep"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4316","article-title":"Association of TP53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer","volume":"28","author":"Deneka AY","year":"2022","unstructured":"Deneka AY, Baca Y, Serebriiskii IG, et al.. Association of TP53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer. Clin Cancer Res. 2022, 28:1925-37. 10.1158\/1078-0432.CCR-21-4316","journal-title":"Clin Cancer Res"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2017.00084","article-title":"More is better: Recent progress in multi-omics data integration methods","volume":"8","author":"Huang S","year":"2017","unstructured":"Huang S, Chaudhary K, Garmire LX. More is better: Recent progress in multi-omics data integration methods. Front Genet. 2017, 8:84. 10.3389\/fgene.2017.00084","journal-title":"Front Genet"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0252-y","article-title":"Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology","volume":"16","author":"Bera K","year":"2019","unstructured":"Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019, 16:703-15. 10.1038\/s41571-019-0252-y","journal-title":"Nat Rev Clin Oncol"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.09","article-title":"Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma","volume":"6","author":"Chatwal MS","year":"2023","unstructured":"Chatwal MS, Chahoud J, Spiess PE. Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma. Cancer Drug Resist. 2023, 6:314-26. 10.20517\/cdr.2023.09","journal-title":"Cancer Drug Resist"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21880","article-title":"Novel clinical trial designs emerging from the molecular reclassification of cancer","volume":"75","author":"Nikanjam M","year":"2025","unstructured":"Nikanjam M, Kato S, Allen T, Sicklick JK, Kurzrock R. Novel clinical trial designs emerging from the molecular reclassification of cancer. CA Cancer J Clin. 2025, 75:243-67. 10.3322\/caac.21880","journal-title":"CA Cancer J Clin"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0267","article-title":"Established and emerging biomarkers of immunotherapy in renal cell carcinoma","volume":"16","author":"Jani Y","year":"2024","unstructured":"Jani Y, Jansen CS, Gerke MB, Bilen MA. Established and emerging biomarkers of immunotherapy in renal cell carcinoma. Immunotherapy. 2024, 16:405-26. 10.2217\/imt-2023-0267","journal-title":"Immunotherapy"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.537","article-title":"The power for PD-L1 expression to predict immune checkpoint blockade outcomes is determined by tumor transcriptome","volume":"18","author":"Li A","year":"2023","unstructured":"Li A, Luo L, Du W, et al.. The power for PD-L1 expression to predict immune checkpoint blockade outcomes is determined by tumor transcriptome. J Thorac Oncol. 2023, 18:311-12. 10.1016\/j.jtho.2023.09.537","journal-title":"J Thorac Oncol"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.2217\/thy.11.32","article-title":"mTOR inhibitors in renal cell carcinoma","volume":"8","author":"Battelli C","year":"2011","unstructured":"Battelli C, Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy. 2011, 8:359-67. 10.2217\/thy.11.32","journal-title":"Therapy"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-022-00579-x","article-title":"BAP1 in cancer: epigenetic stability and genome integrity","volume":"13","author":"Caporali S","year":"2022","unstructured":"Caporali S, Butera A, Amelio I. BAP1 in cancer: epigenetic stability and genome integrity. Discov Oncol. 2022, 13:117. 10.1007\/s12672-022-00579-x","journal-title":"Discov Oncol"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063313","article-title":"A molecular perspective on HIF-1\u03b1 and angiogenic stimulator networks and their role in solid tumors: an update","volume":"25","author":"Magar AG","year":"2024","unstructured":"Magar AG, Morya VK, Kwak MK, Oh JU, Noh KC. A molecular perspective on HIF-1\u03b1 and angiogenic stimulator networks and their role in solid tumors: an update. Int J Mol Sci. 2024, 25:3313. 10.3390\/ijms25063313","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430184-sarcomatoid-and-unclassified-renal-neoplasms-histology-immunology-and-genomics","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T22:45:10Z","timestamp":1763592310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430184-sarcomatoid-and-unclassified-renal-neoplasms-histology-immunology-and-genomics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":151,"URL":"https:\/\/doi.org\/10.7759\/cureus.97268","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}